# Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis

> **NCT05640245** · PHASE2 · COMPLETED · sponsor: **MoonLake Immunotherapeutics AG** · enrollment: 207 (actual)

## Conditions studied

- Arthritis, Psoriatic

## Interventions

- **DRUG:** Sonelokimab
- **DRUG:** Placebo
- **DRUG:** Adalimumab

## Key facts

- **NCT ID:** NCT05640245
- **Lead sponsor:** MoonLake Immunotherapeutics AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-13
- **Primary completion:** 2023-09-05
- **Final completion:** 2024-01-15
- **Target enrollment:** 207 (ACTUAL)
- **Last updated:** 2024-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05640245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05640245, "Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05640245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*